| Outcome Measures: |
Primary: Pharmacokinetics: Maximum Concentration (Cmax) of Dulaglutide, Pharmacokinetic parameters were assessed on Day 1 in Part A and Days 1 and 22 in Part B., Pre-dose and 12, 24, 48, 72, 96, 168, and 336 hours post-dose|Pharmacokinetics: Time of Maximum Observed Concentration (Tmax) of Dulaglutide, Pharmacokinetic parameters were assessed on Day 1 in Part A and Days 1 and 22 in Part B., Pre-dose and 12, 24, 48, 72, 96, 168, and 336 hours post-dose|Pharmacokinetics: Area Under the Concentration-time Curve From Time Zero to 336 Hours Postdose (AUC[0-336]) of Dulaglutide, Pharmacokinetic parameters were assessed on Day 1 in Part A and Days 1 and 22 in Part B., Pre-dose and 12, 24, 48, 72, 96, 168, and 336 hours post-dose|Pharmacokinetics: Half-life of Dulaglutide, Pharmacokinetic parameters were assessed on Day 1 in Part A and Days 1 and 22 in Part B., Pre-dose and 12, 24, 48, 72, 96, 168, and 336 hours post-dose | Secondary: Part B - Pharmacodynamics: Area Under the Plasma Glucose Time Curve From Time Zero to 4 Hours Postmeal (gAUC[0-4]), Pharmacodynamic parameters were assessed at baseline and on Days 3, 24, and 29 in Part B., Baseline and Days 3, 24, and 29
|
| Locations: |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beijing, 100034, China
|
